Evidence map›Paper›PMID 40425588›Full record

ArticleSchizophrenia (Heidelberg, Germany)2025

Healthcare resource utilization burden associated with cognitive impairments identified through natural language processing among patients with schizophrenia in the United States.

Jerome Vaccaro, Mona Nili, Pin Xiang, James K Nelson, Cory Pack, Randall Thompson, Joe Vasey, Joseph Parks

Abstract read
In one paragraph

Article in Schizophrenia (Heidelberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jerome VaccaroRightPath HC, Millerton, NY, USA.
Mona NiliBoehringer Ingelheim Pharmaceutical Inc, Ridgefield, CT, USA. mona.nili@boehringer-ingelheim.com.
Pin XiangBoehringer Ingelheim Pharmaceutical Inc, Ridgefield, CT, USA.
James K NelsonVeradigm Health, Raleigh, NC, USA.ORCID http://orcid.org/0000-0002-4211-4730
Cory PackVeradigm Health, Raleigh, NC, USA.
Randall ThompsonVeradigm Health, Raleigh, NC, USA.
Joe VaseyVeradigm Health, Raleigh, NC, USA.
Joseph ParksNational Council for Behavioral Wellbeing, Washington, DC, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While cognitive impairments in schizophrenia are well documented in research, their identification and impact in clinical practice remain less well understood, despite their association with high patient burden and impact on long-term functional outcomes. In this study we aimed to identify documented cognitive impairments using natural language processing (NLP) and to characterize treatment patterns and healthcare resource utilization (HCRU) among patients with schizophrenia. This US retrospective cohort study used electronic health records (EHR) linked to administrative claims data from January 2016 through February 2023. Adult patients (≥18 years) with at least two schizophrenia diagnosis codes were included. Cognitive impairments were identified by NLP. Patient characteristics were assessed in the 12 months preceding the index date (first documented schizophrenia diagnosis). Treatment patterns and HCRU were measured over the 12 months after index date. A total of 79,326 patients were enrolled in the EHR cohort and 19,974 (25.2%) had documented cognitive impairments. Impairments in "Reasoning and Problem Solving" were identified most often (70.4%) followed by "Working Memory" (27.1%) and "Attention and Vigilance" (19.2%). In the EHR cohort, 11,293 patients (14.2%) had linked claims. Patients with documented cognitive impairments had more HCRU including outpatient visits, psychosocial interventions, and all-cause healthcare claims than patients without documented cognitive impairments (all p < 0.001). Patients with cognitive impairments had greater psychiatric pharmacy utilization than those without cognitive impairments. These observational data add to the limited published literature on cognitive impairments in patients with schizophrenia in the US. The low documented identification of cognitive impairments in this study underscores the importance of improving recognition and documentation of this important domain of schizophrenia. The association of cognitive impairments with high healthcare utilization further emphasizes the need for better treatment options for patients with schizophrenia.

Identifiers

PMID40425588
PMCPMC12116770

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.